CJC-1295 with DAC
MetabolicFor metabolic-syndrome, type-2-diabetes-spectrum, and obesity-medicine indications, CJC-1295 with DAC is one component in a multi-layer protocol. Binds the GHRH receptor on somatotrophs to stimulate endogenous GH release The maleimide-based Drug Affinity Complex (DAC) tail covalently binds serum albumin, extending half-life from minutes to days. Stimulates pulsatile GH secretion that elevates baseline IGF-1.. CGM-tracked individual response in the first cycle, paired with adequate protein intake and resistance training, is the practical framework for evaluating whether CJC-1295 with DAC contributes meaningfully at the 1-2 mg 1-2x weekly dose.
Key Takeaways
Metabolic lens: CJC-1295 with DAC is tracked against glycemic, insulin sensitivity, visceral adiposity, and inflammatory markers. Mechanism: Binds the GHRH receptor on somatotrophs to stimulate endogenous GH release. Metabolic monitoring: baseline HbA1c, fasting glucose, fasting insulin, HOMA-IR, hsCRP, ALT/AST; ideally CGM in first cycle. Metabolic dose: 1-2 mg 1-2x weekly via subq. Metabolic-medicine stack partners: Semaglutide (GLP-1), Cagrilintide, MOTS-c.
For metabolic-medicine applications, the relevant question is which of the four primary axes CJC-1295 with DAC's mechanism engages: incretin-amylin, AMPK-mitochondrial, visceral-fat-cardiometabolic, or the appetite-and-satiety circuit. Binds the GHRH receptor on somatotrophs to stimulate endogenous GH release. The maleimide-based Drug Affinity Complex (DAC) tail covalently binds serum albumin, extending half-life from minutes to days. Stimulates pulsatile GH secretion that elevates baseline IGF-1. The subsections below address each in turn.
AMPK and mitochondrial signalling
Independent of insulin-receptor pharmacology, several peptides in this category engage AMPK and mitochondrial biogenesis pathways. CJC-1295 with DAC engages this layer indirectly through its effect on adiposity, inflammation, and the broader metabolic milieu. The practical effect is sustained shifts in fasting insulin, fasting glucose, and energy expenditure that are not visible in single-meal glycemic curves but accumulate across a cycle.
Weight management and the appetite circuit
Direct appetite effects are not the principal mechanism, but downstream effects on inflammation and metabolic flexibility translate into sustainable rather than rapid weight management. Pairing with adequate protein intake and resistance training is the standard approach for users targeting weight reduction.
Insulin signalling and glycemic effect
CJC-1295 with DAC's relationship to insulin signalling is one of the central practical considerations. Direct incretin-axis effects are limited, but downstream insulin sensitivity is influenced through inflammatory, mitochondrial, or weight-related mechanisms. The implication for glycemic monitoring is clear: baseline HbA1c, fasting glucose, and — ideally — a CGM during the first cycle for users in or near the diabetes-spectrum range.
CJC-1295 with DAC for appetite regulation is best-evaluated against baseline metabolic markers: fasting glucose, HbA1c, lipid panel, hsCRP, ALT/AST. Response timelines are typically 8–12 weeks for primary endpoints; secondary markers (inflammation, hepatic function) move on similar timescales.
In the metabolic syndrome population, CJC-1295 with DAC for ampk activation produces measurable shifts on the cardiometabolic axis when paired with appropriate dietary and activity inputs. The compound's effect is additive to lifestyle rather than substitutive for it.
Where CJC-1295 with DAC is used for type 2 diabetes research, integration with GLP-1 agonist therapy, AMPK activators, or visceral-fat-selective agents is the standard pattern in metabolic medicine clinics. Mono-therapy is appropriate for first-cycle users and for milder presentations.
CJC-1295 with DAC for fatty liver research is best-evaluated against baseline metabolic markers: fasting glucose, HbA1c, lipid panel, hsCRP, ALT/AST. Response timelines are typically 8–12 weeks for primary endpoints; secondary markers (inflammation, hepatic function) move on similar timescales.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | SubQ | 1-2 mg | 8–12 weeks on / 4 weeks off |
| Conservative starter | SubQ | 1-2 mg | 4–6 weeks initial cycle |
| Metabolic focus | SubQ | 1-2 mg | 1-2x weekly |
| Maintenance phase | SubQ | 1-2 mg | Ongoing with periodic pauses |
Dose timing for CJC-1295 with DAC is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses. Fasted dosing produces stronger GH pulses; meal-paired dosing blunts the response.
CJC-1295 with DAC stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from metabolic medicine specialists.
- CJC-1295 with DAC + Semaglutide (GLP-1): Selective GLP-1 receptor agonist. Pairs naturally with CJC-1295 with DAC's mechanism in metabolic / endocrine protocols.
- CJC-1295 with DAC + Cagrilintide: Selectively activates the amylin receptor (calcitonin receptor + RAMP1/3 complex). Pairs naturally with CJC-1295 with DAC's mechanism in metabolic / endocrine protocols.
- CJC-1295 with DAC + MOTS-c: Translocates to the nucleus under metabolic stress and activates AMPK signalling. Pairs naturally with CJC-1295 with DAC's mechanism in metabolic / endocrine protocols.
- CJC-1295 with DAC + Tesamorelin: Modified GHRH (1-44) sequence with an N-terminal trans-3-hexenoic acid that confers resistance to DPP-4 cleavage. Pairs naturally with CJC-1295 with DAC's mechanism in metabolic / endocrine protocols.
Sustained IGF-1 elevation; monitor in users at risk of malignancy. Site reactions, transient flushing, water retention possible.
Lens-specific safety considerations for metabolic / endocrine use of CJC-1295 with DAC: Sustained IGF-1 elevation; monitor in users at risk of malignancy. Site reactions, transient flushing, water retention possible. Additional metabolic / endocrine monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| CJC-1295 with DAC | Long-acting GHRH analogue | ~6-8 days (with DAC) | Metabolic |
| Semaglutide (GLP-1) | GLP-1 receptor agonist | ~7 days | The blockbuster GLP-1 receptor agonist with weekly dosing — engineered from native GLP-1 for protease resistance and albumin binding |
| Cagrilintide | Long-acting amylin analogue | ~7 days | A long-acting amylin analogue paired with semaglutide for weight loss results that exceed either drug alone |
| Tesamorelin | Stabilised GHRH analogue | ~30 min | An FDA-approved long-chain GHRH analogue used for HIV-associated lipodystrophy and notable for its consistent effect on visceral adipose reduction |
What metabolic labs should I track?
What weight loss can I expect?
Pancreatitis or thyroid risk?
Will I regain weight after stopping CJC-1295 with DAC?
What is the regulatory status of CJC-1295 with DAC?
How long until I see results from CJC-1295 with DAC?
Start a CJC-1295 with DAC Protocol
Alukard provides physician-supervised metabolic protocols with GMP-certified CJC-1295 with DAC and GMP-certified compounds with comprehensive metabolic and glycemic monitoring.
Get ProtocolQuick Facts
- Molecular weight
- ~3367 Da
- Sequence length
- 30 aa
- Half-life
- ~6-8 days (with DAC)
- WADA
- Banned (S2 class)
- FDA
- Unapproved
- Research
- Phase II human data; widely used off-label
Stack Partners
All metabolic / endocrine applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for CJC-1295 with DAC unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your Metabolic / Endocrine Protocol for CJC-1295 with DAC
Alukard provides physician-supervised metabolic protocols with GMP-certified compounds with comprehensive metabolic and glycemic monitoring.
HIPAA Compliant · GMP Certified · Physician Supervised